Akèy › Twoub depresif majè › Arkansas
Etid klinik pou Twoub depresif majè nan Arkansas
15 etid pou Twoub depresif majè ap chèche patisipan nan sit nan Arkansas.
Vil nan Arkansas
Tèks ofisyèl etid la (Anglè)
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Oct 1, 2026 · NCT07573176Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 25, 2026 · NCT06559306Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Little Rock
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 24, 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Bryant
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07105111A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Pillar Clinical Research, Bentonville
- SanRo Clinical Research Group, Bryant
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 8, 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Little Rock
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT07610473A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Bentonville
- Draig Clinical Site, Little Rock
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Aug 26, 2026 · NCT07300969NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Bryant
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06911112A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Preferred Research Partners, Inc., Little Rock
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Aug 10, 2026 · NCT07592689A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Woodland International Research Group, Little Rock
- Woodland Research Northwest, Rogers
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Aug 3, 2026 · NCT06775379Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Bryant
- Neurocrine Clinical Site, Little Rock
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT06966401A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Preferred Research Partners /ID# 279206, Little Rock
- Woodland International Research Group /ID# 277605, Little Rock
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Jun 15, 2026 · NCT07276997A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Pillar Clinical Research, LLC, Little Rock
- Preferred Research Partners, Inc., Little Rock
- Woodland Research Northwest, Rogers
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou May 11, 2026 · NCT06524830Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Little Rock
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 29, 2025 · NCT06786624Study of ALTO-300 in MDD
- Site 193, Rogers
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Jul 24, 2025 · NCT05922878Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.